Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status:
Terminated
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, single-arm, open-label, multi-center study to establish the safety and
efficacy of Troxatyl™ (troxacitabine) administered as a continuous infusion for 5 days to
subjects with AML.